BeOne Medicines annual current ratio
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BeOne Medicines Current Ratio Growth & History (ONC)
BeOne Medicines's current ratio was 3.41 for fiscal 2025.
View full BeOne Medicines company overviewBeOne Medicines annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 3.41 | 1.61 | +89.14% |
| 2024 | 2024-12-31 | 1.80 | −0.52 | −22.39% |
| 2023 | 2023-12-31 | 2.32 | −1.22 | −34.51% |
| 2022 | 2022-12-31 | 3.55 | −1.21 | −25.51% |
| 2021 | 2021-12-31 | 4.76 | 0.15 | +3.17% |
| 2020 | 2020-12-31 | 4.61 | 0.83 | +22.09% |
| 2019 | 2019-12-31 | 3.78 | −4.11 | −52.09% |
| 2018 | 2018-12-31 | 7.89 | 1.80 | +29.50% |
| 2017 | 2017-12-31 | 6.09 | −4.59 | −42.97% |
| 2016 | 2016-12-31 | 10.68 | 7.66 | +253.46% |
| 2015 | 2015-12-31 | 3.02 | — | — |
BeOne Medicines quarterly current ratio
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 3.40 | 1.45 | +74.57% |
| Q1 2026 | 2026-03-31 | 3.64 | 1.68 | +85.52% |
| Q4 2025 | 2025-12-31 | 3.41 | 1.61 | +89.14% |
| Q3 2025 | 2025-09-30 | 2.39 | 0.46 | +23.83% |
| Q2 2025 | 2025-06-30 | 1.95 | −0.03 | −1.50% |
| Q1 2025 | 2025-03-31 | 1.96 | −0.11 | −5.42% |
| Q4 2024 | 2024-12-31 | 1.80 | −0.52 | −22.39% |
| Q3 2024 | 2024-09-30 | 1.93 | −1.23 | −38.85% |
| Q2 2024 | 2024-06-30 | 1.98 | −1.15 | −36.79% |
| Q1 2024 | 2024-03-31 | 2.08 | −1.67 | −44.62% |
| Q4 2023 | 2023-12-31 | 2.32 | −1.22 | −34.51% |
| Q3 2023 | 2023-09-30 | 3.16 | −0.91 | −22.46% |
| Q2 2023 | 2023-06-30 | 3.13 | −1.41 | −30.97% |
| Q1 2023 | 2023-03-31 | 3.75 | −1.30 | −25.72% |
| Q4 2022 | 2022-12-31 | 3.55 | −1.21 | −25.51% |
| Q3 2022 | 2022-09-30 | 4.07 | 0.68 | +19.87% |
| Q2 2022 | 2022-06-30 | 4.54 | 0.67 | +17.47% |
| Q1 2022 | 2022-03-31 | 5.05 | 0.43 | +9.25% |
| Q4 2021 | 2021-12-31 | 4.76 | 0.15 | +3.17% |
| Q3 2021 | 2021-09-30 | 3.40 | −4.29 | −55.81% |
| Q2 2021 | 2021-06-30 | 3.86 | −2.29 | −37.23% |
| Q1 2021 | 2021-03-31 | 4.62 | −3.34 | −41.93% |
| Q4 2020 | 2020-12-31 | 4.61 | 0.83 | +22.09% |
| Q3 2020 | 2020-09-30 | 7.69 | 2.29 | +42.35% |
| Q2 2020 | 2020-06-30 | 6.15 | −0.31 | −4.76% |
| Q1 2020 | 2020-03-31 | 7.96 | 0.43 | +5.77% |
| Q4 2019 | 2019-12-31 | 3.78 | −4.11 | −52.09% |
| Q3 2019 | 2019-09-30 | 5.40 | −6.17 | −53.31% |
| Q2 2019 | 2019-06-30 | 6.46 | −1.67 | −20.56% |
| Q1 2019 | 2019-03-31 | 7.52 | −3.65 | −32.67% |
| Q4 2018 | 2018-12-31 | 7.89 | 1.80 | +29.50% |
| Q3 2018 | 2018-09-30 | 11.57 | 2.24 | +24.04% |
| Q2 2018 | 2018-06-30 | 8.14 | −0.25 | −2.94% |
| Q1 2018 | 2018-03-31 | 11.18 | 4.45 | +66.16% |
| Q4 2017 | 2017-12-31 | 6.09 | −4.59 | −42.97% |
| Q3 2017 | 2017-09-30 | 9.33 | 2.17 | +30.25% |
| Q2 2017 | 2017-06-30 | 8.38 | −2.99 | −26.30% |
| Q1 2017 | 2017-03-31 | 6.73 | −9.18 | −57.73% |
| Q4 2016 | 2016-12-31 | 10.68 | 7.66 | +253.46% |
| Q3 2016 | 2016-09-30 | 7.16 | — | — |
| Q2 2016 | 2016-06-30 | 11.37 | — | — |
| Q1 2016 | 2016-03-31 | 15.91 | — | — |
| Q4 2015 | 2015-12-31 | 3.02 | — | — |
BeOne Medicines current ratio trends
Over the last five fiscal years, BeOne Medicines's current ratio decreased from 4.61 to 3.41, a change of −1.21. The latest reported quarter, Q2 2026, shows 3.40.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BeOne Medicines source filings ↗Community posts
BeOne’s initial clinical results support planned late-stage studies
BeOne Medicines ($ONC) disclosed new dose-optimization findings for BGB-B2033 in heavily pretreated liver cancer. At the proposed Phase 3 dose, the bispecific antibody produced confirmed responses in 36% of patients, with an estimated 74.1% ...
